Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The FDA has approved the use of Spravato, an antidepressant nasal spray, as a standalone treatment for depression in the U.S. Sue Varma discusses why she supports the use of the drug and how it may ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

According to J&J, Spravato is an N-methyl-D-aspartate (NMDA ... “Ketamine is a safe medication when used under appropriate professional supervision, so FDA approval will lead to a safer ...

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

Johnson & Johnson reported that Spravato treated over 100,000 patients in 77 countries worldwide, including roughly 80,000 in ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

Spravato targets the neurotransmitter glutamate; however, the mechanism by which esketamine exerts its antidepressant effect is unknown. In an effort to ensure the safe and appropriate use of ...